	US 12,138,278 B2
	Topical compositions
Varsha Bhatt, San Francisco, CA (US); Radhakrishnan Pillai, Santa Rosa, CA (US); and Arturo Angel, Santa Rosa, CA (US)
Assigned to BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed by BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed on Apr. 18, 2024, as Appl. No. 18/639,630.
Application 18/639,630 is a continuation of application No. 17/835,935, filed on Jun. 8, 2022.
Application 17/835,935 is a continuation of application No. 16/945,067, filed on Jul. 31, 2020, granted, now 11,389,467, issued on Jul. 19, 2022.
Claims priority of provisional application 62/881,836, filed on Aug. 1, 2019.
Prior Publication US 2024/0261314 A1, Aug. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7056 (2006.01); A61K 8/22 (2006.01); A61K 8/34 (2006.01); A61K 8/49 (2006.01); A61K 8/73 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/192 (2006.01); A61K 31/327 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61P 17/10 (2006.01); A61Q 19/00 (2006.01)

CPC A61K 31/7056 (2013.01) [A61K 8/22 (2013.01); A61K 8/345 (2013.01); A61K 8/4913 (2013.01); A61K 8/731 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 31/192 (2013.01); A61K 31/327 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61P 17/10 (2018.01); A61Q 19/005 (2013.01)]

20 Claims

1. A topical gel formulation comprising:

1-1.5 wt. % clindamycin phosphate;

2.5-3.5 wt. % benzoyl peroxide;

about 0.15-0.2 wt. % adapalene;

a gelling agent;

an additional agent as a polyhydric alcohol; and

water,

wherein the ratio by weight of water to polyhydric alcohol in the formulation is 10:1 to 20:1, respectively, and the formulation is stable at room temperature for at least six weeks.